These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37599456)

  • 1. Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and
    Wang L; Song J; Xiao X; Li D; Liu T; He X
    J Chemother; 2024 May; 36(3):202-207. PubMed ID: 37599456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
    Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD
    Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
    Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
    Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
    [No Abstract]   [Full Text] [Related]  

  • 4. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
    DiNardo CD; Schuh AC; Stein EM; Montesinos P; Wei AH; de Botton S; Zeidan AM; Fathi AT; Kantarjian HM; Bennett JM; Frattini MG; Martin-Regueira P; Lersch F; Gong J; Hasan M; Vyas P; Döhner H
    Lancet Oncol; 2021 Nov; 22(11):1597-1608. PubMed ID: 34672961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
    Stein EM; DiNardo CD; Fathi AT; Mims AS; Pratz KW; Savona MR; Stein AS; Stone RM; Winer ES; Seet CS; Döhner H; Pollyea DA; McCloskey JK; Odenike O; Löwenberg B; Ossenkoppele GJ; Patel PA; Roshal M; Frattini MG; Lersch F; Franovic A; Nabhan S; Fan B; Choe S; Wang H; Wu B; Hua L; Almon C; Cooper M; Kantarjian HM; Tallman MS
    Blood; 2021 Apr; 137(13):1792-1803. PubMed ID: 33024987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Venetoclax and Azacitidine in Acute Myeloid Leukemia Compared to Azacitidine Monotherapy: Real-World Experience.
    Baba Y; Hida N; Sambe T; Abe M; Kabasawa N; Sakai H; Yoshimura K; Fukuda T
    Anticancer Res; 2024 May; 44(5):2003-2007. PubMed ID: 38677735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2-Mutant Acute Myeloid Leukemia.
    Fan B; Chen Y; Yin F; Hua L; Almon C; Nabhan S; Cooper M; Yang H; Hossain M
    Clin Pharmacol Drug Dev; 2022 Apr; 11(4):429-441. PubMed ID: 35166065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
    Pasvolsky O; Shimony S; Ram R; Shimoni A; Shargian L; Avni B; Wolach O; Shochat T; Yerushalmi R; Amit O; Raanani P; Yeshurun M
    Ann Hematol; 2022 Feb; 101(2):379-387. PubMed ID: 34628534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Short-term Effect of Venetoclax Combined with Azacitidine and "7+3" Regimen in the Treatment of Newly Diagnosed Elder Patients with Acute Myeloid Leukemia].
    Liu XX; Wen XL; Li RQ; Zhang XL; Zhang TB; Dong CX; Wang MF; Zhang JH; Yang LH; Zhang RJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):96-103. PubMed ID: 38387906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia.
    Cherry EM; Abbott D; Amaya M; McMahon C; Schwartz M; Rosser J; Sato A; Schowinsky J; Inguva A; Minhajuddin M; Pei S; Stevens B; Winters A; Jordan CT; Smith C; Gutman JA; Pollyea DA
    Blood Adv; 2021 Dec; 5(24):5565-5573. PubMed ID: 34610123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-institution experience of venetoclax combined with azacitidine in newly diagnosed acute myeloid leukemia patients.
    Yu H; Wang C; Lei Y; Li L; Wang H; Wang G; Xing L; Guan J; Song J; Wu Y; Liu H; Qu W; Wang X; Shao Z; Fu R
    Int Immunopharmacol; 2024 Jan; 127():111232. PubMed ID: 38091830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The Efficacy and Safety of Venetoclax Combined with Azacitidine in the Treatment of Adult Patients with Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy].
    Wang KY; Fan BR; Zhang QW; Han MR; Ge XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):342-346. PubMed ID: 38660834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with
    Bewersdorf JP; Patel KK; Goshua G; Shallis RM; Podoltsev NA; Stahl M; Stein EM; Huntington SF; Zeidan AM
    Leuk Lymphoma; 2023 Feb; 64(2):454-461. PubMed ID: 36493798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of Venetoclax Plus Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia Patients with
    Weng GY; You WW; Liu HX; Cai Y; DU X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1333-1339. PubMed ID: 37846681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Venetoclax and azacitidine induced cytogenetic response in an elderly patient with IDH2- and DNMT3A-mutated refractory acute myeloid leukemia].
    Kunisada K; Matsuoka A; Yoshida S; Taoka T
    Rinsho Ketsueki; 2022; 63(12):1621-1625. PubMed ID: 36653133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.
    Petit C; Saillard C; Mohty B; Hicheri Y; Villetard F; Maisano V; Charbonnier A; Rey J; D'Incan E; Rouzaud C; Gelsi-Boyer V; Murati A; Lhoumeau AC; Ittel A; Mozziconacci MJ; Alary AS; Hospital MA; Vey N; Garciaz S
    Eur J Haematol; 2024 Apr; 112(4):530-537. PubMed ID: 38031389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations.
    Pollyea DA; DiNardo CD; Arellano ML; Pigneux A; Fiedler W; Konopleva M; Rizzieri DA; Smith BD; Shinagawa A; Lemoli RM; Dail M; Duan Y; Chyla B; Potluri J; Miller CL; Kantarjian HM
    Clin Cancer Res; 2022 Jul; 28(13):2753-2761. PubMed ID: 35046058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia.
    Cui J; Chen X; Li C; Yan Q; Yuan G
    Hematology; 2024 Dec; 29(1):2293512. PubMed ID: 38095287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
    Lachowiez CA; Reville PK; Kantarjian H; Jabbour E; Borthakur G; Daver N; Issa G; Furudate K; Tanaka T; Pierce S; Tang G; Patel KP; Medeiros J; Abbas HA; Haddad F; Hammond D; Short NJ; Maiti A; Yilmaz M; Sasaki K; Takahashi K; Pemmaraju N; Konopleva M; Garcia-Manero G; Ravandi F; Kadia TM; Loghavi S; DiNardo CD
    Am J Hematol; 2022 Nov; 97(11):1443-1452. PubMed ID: 36054614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation.
    Woods A; Norsworthy KJ; Wang X; Vallejo J; Chiu Yuen Chow E; Li RJ; Sun J; Charlab R; Jiang X; Pazdur R; Theoret MR; de Claro RA
    Clin Cancer Res; 2024 Apr; 30(7):1226-1231. PubMed ID: 38010220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.